Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
← catalyst calendarNCT03368742 · readout in 57 d
Sponsored by Solid Biosciences Inc. (industry) · SLDB — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
12actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-12-06 | actual | When the study began enrolling |
| Primary completion | 2026-10-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-15 | estimated | The whole study's end, after follow-up |
| First posted | 2017-12-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Duchenne Muscular Dystrophy
Intervention
- Genetic: SGT-001
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Treatment Emergent Adverse Events (TEAEs)
measured Up to 5 years
Publications
- PMID 38229112 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SLDB's whole pipeline · Catalyst calendar · Every registered study · What changed